Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02103894 · ClinicalTrials.gov registry record · Phase 1
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
A Phase 1 study of Parkinsons Disease (PD) and Tauopathies, sponsored by Molecular NeuroImaging.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02103894 is a Phase 1 study of Parkinsons Disease (PD) and Tauopathies that has completed, run by Molecular NeuroImaging. The registered enrollment target is 16 participants, below the 119-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02103894, a Phase 1 study of Parkinsons Disease (PD) and Tauopathies, has completed, sponsored by Molecular NeuroImaging.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to assess \[18F\]MNI-777 PET imaging as a tool to detect tau pathology in the brain of individuals who carry a clinical diagnosis of a tauopathy, including: Alzheimer's Disease (AD),Parkinson's disease (PD) Progressive Supranuclear Palsy (PSP), chronic traumatic encephalopathy (CTE) and Frontal Temporal Dementia (FTD) and age- and gender-matched healthy subjects.
Conditions Studied
Interventions
- DRUG [18F]T807 ([18F]MNI-777)
Study Locations (1)
Connecticut
- Molecular NeuroImaging, LLC - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02103894
The ClinicalTrials.gov registry entry for NCT02103894 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (87% lower). The listed sponsor is Molecular NeuroImaging, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Parkinsons Disease (PD) appearing as the primary indexed condition, and to 1 intervention - of which [18F]T807 ([18F]MNI-777) is the first listed.
NCT02103894 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT02103894 about?
NCT02103894 is a clinical study titled "Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects". The goal of this study is to assess \[18F\]MNI-777 PET imaging as a tool to detect tau pathology in the brain of individuals who carry a clinical diagnosis of a tauopathy, including: Alzheimer's Disease (AD),Parkinson's disease (PD) Progressive Supranuclear Palsy (PSP), chronic traumatic encephalopa...
What is the current status of trial NCT02103894?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-02. Estimated completion is 2016-09.
What conditions does trial NCT02103894 study?
This clinical trial studies the following conditions: Parkinsons Disease (PD), Tauopathies, Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE).
What interventions are being tested in trial NCT02103894?
The interventions under investigation include: [18F]T807 ([18F]MNI-777) (DRUG).
Who is sponsoring clinical trial NCT02103894?
This trial is sponsored by Molecular NeuroImaging, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02103894 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinsons Disease (PD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
COMPLETED · Phase 1
-
A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
COMPLETED · Phase 1
-
Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD
RECRUITING · NA
-
A Study of NE3107 in Early Parkinson's
RECRUITING · Phase 2
-
Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.